Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

BACKGROUND: Combined endocrine therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor has been indicated to improve not only progression-free survival, but also overall survival in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer. However, resistance to this com...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogata, Ryohei, Kishino, Emi, Saitoh, Wataru, Koike, Yoshikazu, Kurebayashi, Junichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796879/
https://www.ncbi.nlm.nih.gov/pubmed/32860163
http://dx.doi.org/10.1007/s12282-020-01150-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796879/
https://www.ncbi.nlm.nih.gov/pubmed/32860163
http://dx.doi.org/10.1007/s12282-020-01150-8

Ejemplares similares